A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors.

⟵ Back to Search Results

Beigene Study ID

BGB-900-103

ClinicalTrials.gov ID

NCT03666143

China Drug Trials ID

CTR20181404

Sex: All

Age: 18 Years / N/A

No Study Documents

Sex: All

Age: 18 Years / N/A

No Study Documents